Van Lanschot Kempen Investment Management N.V. Sells 954 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Van Lanschot Kempen Investment Management N.V. decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 15.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,318 shares of the biopharmaceutical company's stock after selling 954 shares during the quarter. Van Lanschot Kempen Investment Management N.V.'s holdings in Regeneron Pharmaceuticals were worth $3,788,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of REGN. Willner & Heller LLC boosted its stake in Regeneron Pharmaceuticals by 3.9% in the fourth quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company's stock valued at $284,000 after buying an additional 15 shares in the last quarter. OLD Second National Bank of Aurora boosted its stake in shares of Regeneron Pharmaceuticals by 0.5% in the 4th quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company's stock valued at $2,025,000 after purchasing an additional 15 shares in the last quarter. Rakuten Securities Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 15 shares during the last quarter. TD Private Client Wealth LLC increased its position in Regeneron Pharmaceuticals by 9.6% during the 4th quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock worth $122,000 after purchasing an additional 15 shares in the last quarter. Finally, Manchester Capital Management LLC lifted its stake in Regeneron Pharmaceuticals by 12.6% in the 4th quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company's stock valued at $115,000 after purchasing an additional 18 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th. Truist Financial dropped their target price on Regeneron Pharmaceuticals from $1,004.00 to $975.00 and set a "buy" rating for the company in a research report on Wednesday. Canaccord Genuity Group raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 22nd. UBS Group lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. Finally, Robert W. Baird cut their target price on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a research report on Friday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $945.32.

Regeneron Pharmaceuticals Stock Up 0.5 %

Shares of Regeneron Pharmaceuticals stock traded up $2.88 on Friday, hitting $602.64. The company had a trading volume of 964,377 shares, compared to its average volume of 724,654. Regeneron Pharmaceuticals, Inc. has a 1 year low of $525.99 and a 1 year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The stock has a 50 day moving average of $637.38 and a 200-day moving average of $721.91. The stock has a market capitalization of $65.88 billion, a price-to-earnings ratio of 15.74, a P/E/G ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion for the quarter, compared to analysts' expectations of $3.76 billion. During the same period last year, the business earned $11.86 EPS. The business's revenue was up 10.3% on a year-over-year basis. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were paid a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.58%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.